Pharmanet Names Poseneer to Neuroscience Position

Joel Posener, M.D., has joined PharmaNet Development Group as executive medical director, Neuroscience. Dr. Posener will support PharmaNet project teams conducting clinical trials in psychiatry and neurology, and will provide drug development advice to clients in the area of neuroscience.

“We are thrilled Joel has joined PharmaNet,” said Steven Leventer, Ph.D., vice president and general manager, Neuroscience. “His distinguished medical and clinical credentials will be a valuable addition to PharmaNet’s experienced neuroscience team. Joel’s appointment further demonstrates our commitment to help our clients develop innovative neuroscience therapeutics.”

Prior to joining PharmaNet, Dr. Posener held roles at Wyeth as senior director, Neuroscience Medical Research and senior director, Early Development and Clinical Pharmacology. He directed Phase II projects in a variety of psychiatric indications including cognitive impairment in schizophrenia, bipolar disorder and depression. Dr. Posener has also managed early clinical development programs in schizophrenia, depression and Alzheimer’s disease.

Dr. Posener obtained his medical degree from McGill University, completed a residency in psychiatry and fellowship in psychiatric research at Harvard Medical School and Massachusetts Mental Health Center, and is board certified in Psychiatry. Before joining the pharmaceutical industry, he served on the faculty of Harvard Medical School and Washington University School of Medicine in St. Louis.